<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672812</url>
  </required_header>
  <id_info>
    <org_study_id>87650318100005327</org_study_id>
    <nct_id>NCT03672812</nct_id>
  </id_info>
  <brief_title>The Use of Liraglutide in Brain Death</brief_title>
  <official_title>Randomized Clinical Trial to Evaluate the Use of Liraglutide in Individuals With Brain Death and Anti-inflammatory and Anti-apoptotic Effects on Organs to be Transplanted</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence of the association of brain death and inflammation, affecting outcomes of
      transplanted organs, but in a way not fully understood. Observational studies suggest that
      the use of target-guided therapies has a beneficial effect in reducing the rate of donor loss
      due to cardiac arrest and increasing the rate of donor-picked organs, which will be tested
      through the randomized clinical trial. However, no study so far has directly tested the
      effect of drugs with anti-inflammatory and anti-apoptotic properties administered to the
      donor in encephalic death in reducing inflammation of organs to be transplanted. This study
      aims to evaluate the use of liraglutide in patients with brain death in relation to their
      ability to attenuate the inflammation induced by encephalic death by means of a randomized
      clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intervention group will be composed of individuals deceased in brain dead, after the
      conclusion of the brain dead protocol by the teams responsible for the Intensive care and
      will receive liraglutide. The control group will be composed of the same population of
      individuals who died in brain dead of the intervention group, but will receive a placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">February 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change inflammation</measure>
    <time_frame>from 6 hours to 24 hours</time_frame>
    <description>change interleukin 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change inflammation with liraglutide</measure>
    <time_frame>from 6 to 24 hours</time_frame>
    <description>change interleukin 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change inflammation liraglutide group</measure>
    <time_frame>from 6 to 24 hours</time_frame>
    <description>change interleukin 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change inflammation intervention group</measure>
    <time_frame>from 6 to 24 hours</time_frame>
    <description>change tumor necrosis factor-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change inflammation</measure>
    <time_frame>from 6 to 24 hours</time_frame>
    <description>change interferon gamma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Death</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>0,5ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0,5ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>liraglutide 3mg 6/6 hours</description>
    <arm_group_label>liraglutide</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  individuals deceased more than 18 years after the end of the brain death protocol

        Exclusion Criteria:

          -  Pregnant women, patients with advanced renal failure on hemodialysis, with hepatic
             insufficiency or allergy known to liraglutide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristiane Leitao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristiane Leitao, PhD</last_name>
    <phone>51 99655618</phone>
    <email>crisbleitao@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana Rech, PhD</last_name>
    <phone>51 99593669</phone>
    <email>threch@hcpa.edu.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Santa Isabel</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <zip>89010380</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geisiane Custodio, Master</last_name>
      <phone>47 991335153</phone>
      <email>geisiane_c@yahoo.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 27, 2018</last_update_submitted>
  <last_update_submitted_qc>September 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liraglutide</keyword>
  <keyword>brain death</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

